Pipeline

CEND-1 + gemcitabine/nab-paclitaxel

Indication // Pancreatic ductal adenocarcinoma (PDAC)

Pancreatic cancer represents a high unmet medical need. Current standard-of-care chemotherapy is limited by poor ability to target and penetrate dense tumor stroma. Based on encouraging Phase 1 clinical trial results, Cend is advancing development to more effectively target and treat PDAC.

Pre
clinical
Phase 1Phase 2Phase 3Rights
Cend

CEND-1 + SoC chemo + anti-PD(L)1

Indication // Pancreatic ductal adenocarcimona (PDAC)

Effectiveness of immunotherapies, including checkpoint inhibitor antibody drugs, has been limited by poor ability to penetrate PDAC stroma and an immunosuppressive tumor microenvironment. Cend is advancing development to enhance penetration of checkpoint inhibitors and targeted depletion of tumor-infiltrating immunosuppressive cells to enhance effectiveness of immunotherapy in combination with chemotherapy.

Pre
clinical
Phase 1Phase 2Phase 3Rights
Cend

CEND-1 + SoC chemo + anti-PD(L)1

Indication // Solid tumor cancers

Cend’s treatment approach may enhance ability to target and penetrate a range of solid tumor cancer types as well as reduce their immunosuppressive tumor microenvironments to enable the patients’ immune systems and/or immunotherapies to more effectively fight their cancers.

Pre
clinical
Phase 1Phase 2Phase 3Rights
Cend

Ras pathway modulator

Indication // PDAC / other Ras-driven cancers

Over 90% of pancreatic cancers are driven by dysregulation of Ras and the MAPK pathway. Cend is advancing a program to address resistance mechanism associated with other Ras-targeted approaches.

Pre
clinical
Phase 1Phase 2Phase 3Rights
Cend
  • Product
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Rights

(Phase 2 2021)

Cend

CEND-1 + gemcitabine/nab-paclitaxel

Indication // Pancreatic ductal adenocarcinoma (PDAC)

Pancreatic cancer represents a high unmet medical need. Current standard-of-care chemotherapy is limited by poor ability to target and penetrate dense tumor stroma. Based on encouraging Phase 1 clinical trial results, Cend is advancing development to more effectively target and treat PDAC.

(IND 2021)

Cend

CEND-1 + SoC chemo + anti-PD(L)1

Indication // Pancreatic ductal adenocarcimona (PDAC)

Effectiveness of immunotherapies, including checkpoint inhibitor antibody drugs, has been limited by poor ability to penetrate PDAC stroma and an immunosuppressive tumor microenvironment. Cend is advancing development to enhance penetration of checkpoint inhibitors and targeted depletion of tumor-infiltrating immunosuppressive cells to enhance effectiveness of immunotherapy in combination with chemotherapy.

(IND 2021)

Cend

CEND-1 + SoC chemo + anti-PD(L)1

Indication // Solid tumor cancers

Cend’s treatment approach may enhance ability to target and penetrate a range of solid tumor cancer types as well as reduce their immunosuppressive tumor microenvironments to enable the patients’ immune systems and/or immunotherapies to more effectively fight their cancers.

(IND 2022)

Cend

Ras pathway modulator

Indication // PDAC / other Ras-driven cancers

Over 90% of pancreatic cancers are driven by dysregulation of Ras and the MAPK pathway. Cend is advancing a program to address resistance mechanism associated with other Ras-targeted approaches.

Clinical Trials

To learn more about available clinical trials and listings click the link below.

clinicaltrials.gov